Amicus Therapeutics Announces Second Quarter 2008 Financi...(st income 1060 1331 1753 ...),Health

Interest expense (86) (59) (179) (129) (1,559)

Change in fair

value of warrant

liability (86) - (149) - (454)

Other expense - - - - (1,180)

Loss before

tax benefit (9,396) (9,219) (19,091) (16,874) (142,404)

(Provision for)/

benefit from

income taxes - (75) - (150) 545

Net loss (9,396) (9,294) (19,091) (17,024) (141,859)

Deemed

dividend - - - - (19,424)

Preferred

stock

accretion (310) - (351) - (802)

Net loss

attributable

to common

stockholders $(9,706) $(9,294) $(19,442) $(17,024) $(162,085)

Net loss

attributable

to common

stockholders

per common

share - basic

and diluted $(1.37) $(0.41) $(4.80) $(0.76)

Weighted-average

common shares

outstanding -

basic and

diluted 7,083,748 22,467,198 4,051,709 22,439,893

Table 2

Amicus Therapeutics, Inc.

Reconciliation of GAAP to non-GAAP Measures for the Statement of Operations Information for Three Months Ended June 30, 2008

(Unaudited)

(In thousands, except share and per share amounts)

Preferred

Stock Stock GAAP as

Non-GAAP Accretion Compensation Reported

Income Statement

Classifications:

Revenue $3,807 $3,807

Research and

developmen
'/>"/>